By mapping the interlocking structures of small molecules and mutated protein "receptors" in non-small cell lung cancer (NSCLC) cells, scientists at Dana-Farber Cancer Institute and their colleagues have energized efforts to design molecules that mesh with these receptors, potentially interfering with cancer cell growth and survival.
In a study published in the March issue of Cancer Cell, researchers led by Michael Eck, MD, PhD, of Dana-Farber used X-ray crystallography to determine the structure of two mutated forms of the epidermal growth factor receptor (EGFR) in lung cancer cells. EGFR, a protein known as a tyrosine kinase, plays a key role in relaying growth signals within cells. When mutated, it can become overactive, leading to excessive cell division and cancer.
"It turns out that in some cases, the very mutation that causes the cancer in the first place is also the cancer’s Achilles’ heel," said Eck, the paper’s senior author. "We now see that inhibitors such as gefitinib actually bind more tightly to some of the cancer-causing mutants, even though they were originally developed to block the normal receptor."
Cai-Hong Yun, PhD, of Dana-Farber is the paper’s first author.
Mutations in the EGFR kinase domain occur in approximately 16 percent of NSCLCs, but at much higher frequencies in selected populations, including nonsmokers, women, and East Asian patients. Laboratory and clinical studies have shown that tyrosine kinase inhibitors are more effective against some EGFR mutations than others, although the molecular reasons for this are unclear. By developing a better understanding of the effect of the mutations on inhibitor binding at a structural level, it may be possible to develop more effective therapies.
In the current study, Eck and his colleagues analyzed the three-dimensional structures of the normal and mutated versions of EGFR bound to several different types of inhibitor molecules. They found that two inhibitors – the drug gefitinib (marketed as Iressa(R), and a compound called AEE788 – bind especially tightly to one of the mutated forms, meaning these inhibitors are potentially more effective at blocking the growth of cancer cells containing that mutation. In the case of gefitinib, it bound 20 times more tightly to the L858R mutant than to the normal, mutation-free EGFR.
The research team concluded that the particular EGFR mutation within tumor cells determines which inhibitor molecules are likely to be able to slow or stop the growth of those cells.
"Although structural divergence in the EGFR mutants may complicate efforts to treat the disease, it may also present an advantage in that it introduces the possibility of developing inhibitors that target specific mutations, which should lead to more effective treatments," said Eck, who also an associate professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. "These targeted therapies likely would be less toxic as they, in theory, would not affect the normal functioning EGFR proteins."
Bill Schaller | EurekAlert!
Embryonic development: How do limbs develop from cells?
18.05.2018 | Humboldt-Universität zu Berlin
Reading histone modifications, an oncoprotein is modified in return
18.05.2018 | American Society for Biochemistry and Molecular Biology
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...
A team led by Austrian experimental physicist Rainer Blatt has succeeded in characterizing the quantum entanglement of two spatially separated atoms by observing their light emission. This fundamental demonstration could lead to the development of highly sensitive optical gradiometers for the precise measurement of the gravitational field or the earth's magnetic field.
The age of quantum technology has long been heralded. Decades of research into the quantum world have led to the development of methods that make it possible...
Cardiovascular tissue engineering aims to treat heart disease with prostheses that grow and regenerate. Now, researchers from the University of Zurich, the Technical University Eindhoven and the Charité Berlin have successfully implanted regenerative heart valves, designed with the aid of computer simulations, into sheep for the first time.
Producing living tissue or organs based on human cells is one of the main research fields in regenerative medicine. Tissue engineering, which involves growing...
A team of scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg investigated optically-induced superconductivity in the alkali-doped fulleride K3C60under high external pressures. This study allowed, on one hand, to uniquely assess the nature of the transient state as a superconducting phase. In addition, it unveiled the possibility to induce superconductivity in K3C60 at temperatures far above the -170 degrees Celsius hypothesized previously, and rather all the way to room temperature. The paper by Cantaluppi et al has been published in Nature Physics.
Unlike ordinary metals, superconductors have the unique capability of transporting electrical currents without any loss. Nowadays, their technological...
02.05.2018 | Event News
13.04.2018 | Event News
12.04.2018 | Event News
18.05.2018 | Power and Electrical Engineering
18.05.2018 | Information Technology
18.05.2018 | Information Technology